D'ADDA, Mariella
 Distribuzione geografica
Continente #
NA - Nord America 189
EU - Europa 145
AS - Asia 132
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 469
Nazione #
US - Stati Uniti d'America 188
CN - Cina 77
SG - Singapore 41
RU - Federazione Russa 33
IE - Irlanda 23
SE - Svezia 22
FR - Francia 20
GB - Regno Unito 17
DE - Germania 11
IT - Italia 9
KR - Corea 8
FI - Finlandia 4
VN - Vietnam 3
HK - Hong Kong 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
ES - Italia 1
HU - Ungheria 1
ID - Indonesia 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
TG - Togo 1
Totale 469
Città #
Chandler 73
Singapore 29
Beijing 26
Dublin 23
Southend 13
Lawrence 9
Princeton 9
Sindelfingen 9
Seoul 8
Jinan 6
Wilmington 6
Falls Church 4
Helsinki 4
Los Angeles 4
Zhengzhou 4
Chengdu 3
Norwalk 3
Shenyang 3
Wayne 3
Ashburn 2
Florence 2
Hong Kong 2
London 2
New York 2
Ningbo 2
Redmond 2
Santa Clara 2
Shanghai 2
Taizhou 2
Tianjin 2
Ann Arbor 1
Boardman 1
Brasov 1
Brescia 1
Buenos Aires 1
Chicago 1
Dong Ket 1
Edinburgh 1
Fairfield 1
Guadalajara 1
Guangzhou 1
Haikou 1
Houston 1
Jacksonville 1
Jakarta 1
Jiaxing 1
Kent 1
Lanzhou 1
Lomé 1
Melbourne 1
Milan 1
Nanjing 1
Newark 1
San Francisco 1
Seattle 1
Sopron 1
Taiyuan 1
Verona 1
Warsaw 1
Totale 290
Nome #
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 66
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 63
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 62
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 56
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 50
BCR}-{ABL}1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by {NGS 47
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 46
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 40
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 38
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial 16
Totale 484
Categoria #
all - tutte 2.516
article - articoli 2.516
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.032


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202042 0 0 0 0 0 0 0 0 0 25 9 8
2020/202136 8 7 0 2 9 3 0 0 1 1 1 4
2021/202248 2 11 3 3 2 2 0 4 5 0 2 14
2022/2023188 9 20 15 21 24 50 0 15 22 2 7 3
2023/202468 3 6 2 12 0 7 1 1 0 17 13 6
2024/2025102 8 13 7 53 8 13 0 0 0 0 0 0
Totale 484